CYP3A5 and acute lymphoblastic leukemia: A small Chinese study including 36 ALL patients showed no association between potential metabolizing CYP3A polymorphisms (CYP3A5*1‐*1, CYP3A5*1‐*3, CYP3A5*3‐*3) and daunorubicin-induced cardiotoxicity (Huang et al., 2017).